Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

What Was Tested

Researchers studied Somatostatin and Pasireotide in this clinical trial, phase ii publication.

Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5).

Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotide in vitro.

Who Took Part

The study group was 17 patients.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as open-label.

Everyone knew when Somatostatin was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

What Was Measured

This open-label, phase II study assessed the clinical activity of pasireotide in treatment-naïve patients with metastatic grade 1 or 2 NETs.

Tumor assessments were performed every 3 months using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Topics PubMed links to this paper include Neoplasm Metastasis, Neuroendocrine Tumors, Pancreatic Neoplasms, Receptors, Somatostatin and Somatostatin.

Author keywords: carcinoid, pasireotide, somatostatin analogs and somatostatin receptors.

What This Means in Plain Language

The paper is an open-label study of Somatostatin and Pasireotide in 17 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2015 (Endocrine-related cancer), a journal based in England.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.